Skip to Main Content
American Flag
LABOR DAY SALE

50% off your first year of any Quiver subscription

...

Use Promo Code:

LABOR26
American Flag
×
Quiver Logo Get a Free Trial on Quiver Premium Today!
Back to News

ResMed Falls After Earnings Despite Beat as Full-Year Outlook Stays Unchanged

None

ResMed (RMD) is down 7.8% today. Here is some analysis on what might have caused this price movement. ([investor.resmed.com](https://investor.resmed.com/_assets/_27e1b3f57702e5c0e956cc5859ae3098/resmed/db/2598/48783/earnings_release/RMD_1Q27_Earnings_Release_29OCT26_vF.pdf))

Analysis: The selloff appears tied less to the quarter itself and more to investor disappointment that management kept its full-year fiscal 2027 guidance unchanged after posting a revenue and earnings beat. Pressure may also be coming from softer operating-margin and cash-flow comparisons, which can matter when expectations are already high. ([investor.resmed.com](https://investor.resmed.com/_assets/_27e1b3f57702e5c0e956cc5859ae3098/resmed/db/2598/48783/earnings_release/RMD_1Q27_Earnings_Release_29OCT26_vF.pdf))

Details:

  • First-quarter revenue rose 6% to about $1.41 billion, while non-GAAP diluted EPS increased 14% to $2.91. ([investor.resmed.com](https://investor.resmed.com/_assets/_27e1b3f57702e5c0e956cc5859ae3098/resmed/db/2598/48783/earnings_release/RMD_1Q27_Earnings_Release_29OCT26_vF.pdf))
  • ResMed left fiscal 2027 guidance unchanged at 5% to 7% core constant-currency revenue growth, reported revenue of $5.75 billion to $5.85 billion, and non-GAAP EPS of $12.00 to $12.25. ([investor.resmed.com](https://investor.resmed.com/_assets/_27e1b3f57702e5c0e956cc5859ae3098/resmed/db/2598/48783/earnings_release/RMD_1Q27_Earnings_Release_29OCT26_vF.pdf))
  • GAAP operating margin narrowed to 32.0% from 33.4% a year earlier, while non-GAAP operating margin edged down to 35.8% from 36.1%, suggesting profitability did not accelerate as much as some investors may have wanted. ([investor.resmed.com](https://investor.resmed.com/_assets/_27e1b3f57702e5c0e956cc5859ae3098/resmed/db/2598/48783/earnings_release/RMD_1Q27_Earnings_Release_29OCT26_vF.pdf))
  • Operating cash flow fell 8% to $422 million and free cash flow fell 10% to $374 million, even though the company returned more than $1.0 billion to shareholders through buybacks and dividends during the quarter. ([investor.resmed.com](https://investor.resmed.com/_assets/_27e1b3f57702e5c0e956cc5859ae3098/resmed/db/2598/48783/earnings_release/RMD_1Q27_Earnings_Release_29OCT26_vF.pdf))
  • Sources:

    ResMed Investor Relations, SEC, MassDevice ([investor.resmed.com](https://investor.resmed.com/_assets/_27e1b3f57702e5c0e956cc5859ae3098/resmed/db/2598/48783/earnings_release/RMD_1Q27_Earnings_Release_29OCT26_vF.pdf))

    Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

    $RMD Insider Trading Activity

    RMD Insider Trades

    $RMD insiders have traded $RMD stock on the open market 8 times in the past 6 months. Of those trades, 0 have been purchases and 8 have been sales.

    Here’s a breakdown of recent trading of $RMD stock by insiders over the last 6 months:

    • MICHAEL J. FARRELL (Chairman and CEO) has made 0 purchases and 5 sales selling 24,955 shares for an estimated $5,325,259.
    • PETER C FARRELL has made 0 purchases and 2 sales selling 8,970 shares for an estimated $2,027,688.
    • MICHAEL J RIDER (Global General Counsel) sold 400 shares for an estimated $102,000

    To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

    $RMD Hedge Fund Activity

    We have seen 393 institutional investors add shares of $RMD stock to their portfolio, and 498 decrease their positions in their most recent quarter.

    Here are some of the largest recent moves:

    To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

    $RMD Price Targets

    Multiple analysts have issued price targets for $RMD recently. We have seen 5 analysts offer price targets for $RMD in the last 6 months, with a median target of $266.0.

    Here are some recent targets:

    • Nathan Treybeck from Wells Fargo set a target price of $225.0 on 07/08/2026
    • Craig Wong-Pan from RBC Capital set a target price of $276.0 on 07/08/2026
    • Justin Patterson from Keybanc set a target price of $266.0 on 06/22/2026
    • David Bailey from Morgan Stanley set a target price of $230.0 on 06/17/2026
    • Laura Sutcliffe from Citigroup set a target price of $270.0 on 06/15/2026

    This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.

    Add Quiver Quantitative to your preferred sources on Google Google News Logo

    Suggested Articles